Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adapted antibiotic therapy vs tetracycline in Hurley stage 2 hidradenitis suppurativa
2022-003562-20Phase 3Active
- Sponsor
- Institut Pasteur
- Start
- Dec 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ceftriaxone, metronidazole, rifampicin, moxifloxacin and tetracycline in hidradenitis suppurativa (HS) (2 arms), sponsored by Institut Pasteur. Primary endpoint: Clinical remission at week 12 (IHS4 improvement ≥90%). Started Dec 2022; status: active.
02
Drugs
ceftriaxonemetronidazolerifampicinmoxifloxacintetracycline
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2022-003562-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003562-20.